Enriching the lives of pets and their owners with breakthrough therapeutics

Areas of Focus

Cardiology

Targeted treatments for complex, chronic heart diseases in cats and dogs

Pain Management

Next generation veterinary pain management for daily use

Gastroenterology

The world’s first veterinary registered PPI for canine gastric ulceration

Wellness Testing

Diagnostics for Gastric markers that indicate health and wellness

Age related decline

Tackling some of the most debilitating and chronic diseases of aging in companion animals

Product Launch Expected:

US product launch Q4 2023
EU launch Q1 2024

Product Launch Expected:

US product launch Q1 2024;
EU launch Q2 2024

Product Launch Expected:

US product launch Q1 2023
EU launch Q3 2023

Product Launch Expected:

US/EU product launch Q2 2023

In research and development
Areas of Focus
Cardiology

Targeted treatments for complex, chronic heart diseases in cats and dogs

Product Launch Expected:

US product launch Q4 2023
EU launch Q1 2024

Pain Management

Next generation veterinary pain management for daily use

Product Launch Expected:

US product launch Q1 2024;
Q2 2024

Gastroenterology

The world’s first veterinary registered PPI for canine gastric ulceration

Product Launch Expected:

US product launch Q1 2023
EU launch Q3 2023

Wellness Testing

Diagnostics for Gastric markers that indicate health and wellness

Product Launch Expected:

US/EU product launch Q2 2023

Age related decline

Tackling some of the most debilitating and chronic diseases of aging in companion animals

In research and development

Our research and development model is simple but effective.

WE IDENTIFY

We identify diseases in companion animals where there are no approved treatments.

WE FORMULATE

We formulate novel solutions with species specific doses and presentations.

WE TRIAL

Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.

WE COLLATE

The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.

WE PROVE

We prove the safety and efficacy of our products to FDA and EMA requirements.

WE TRANSLATE

We harness our extensive animal research to identify synergies in human medicine.

Our research and development model is simple but effective.

WE IDENTIFY

We identify diseases in companion animals where there are no approved treatments.

WE FORMULATE

We formulate novel solutions with species specific doses and presentations.

WE TRIAL

Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.

WE COLLATE

The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.

WE PROVE

We prove the safety and efficacy of our products to FDA and EMA requirements.

WE TRANSLATE

We harness our extensive animal research to identify synergies in human medicine.

Insights

Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.

Spotlight Series - The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State University Veterinary School

Learn more about this exciting study which is open for recruitment. The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State Veterinary School.

November 17, 2022
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022

Dr. Josh Stern to present the positive findings of RAPACAT HCM Clinical Trial this Sunday 02nd October at ICVS 2022

October 1, 2022
TriviumVet to exhibit at VMX 2023. TriviumVet will be participating in the New Exhibitors Area – Zone A – Booth 5203

The annual conference will be held 14 to 18 January in person in Orlando, Florida, at the Orange County Convention Center

September 19, 2022

“Until one has loved an animal, a part of one’s soul remains unawakened”

Anatole France